A Phase 2 interventional study of Carbocaine Injectable Product in Ischemic Stroke, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-26.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 4 of them phase 3. Ischemic Stroke · Assistance Publique - Hôpitaux de Paris.
Among the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 9th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →9 of the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 60–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 38 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 487 across the 14 interventional studies, 1,975 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT06071091Assistance Publique - Hôpitaux de ParisPermanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after subcutaneous administration of mepivacaine. The effect was maintained for several days, and was repeated with each injection of mepivacaine. This clinical improvement is associated with functional changes in the peri-lesional areas on resting-state functional MRI.
The investigator team hypothesizes that in some patients with chronic neurological symptoms of stroke, the investigator team will observe a favorable response to subcutaneous mepivacaine injection.
A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after subcutaneous administration of mepivacaine. The effect was maintained for several days, and was repeated with each injection of mepivacaine. This clinical improvement is associated with functional changes in the peri-lesional areas on resting-state functional MRI. The investigator team hypothesizes that in some patients with chronic neurological symptoms of stroke, investigator team will observe a favorable response to subcutaneous mepivacaine injection.
The team will include patients with clinically significant sequelae of ischemic stroke, as was the case with the initial patient. In addition,
The investigator teamwill therefore include patients with sequelae of at least one of the following three types:
Only patients more than 30 days after the occurrence of the stroke will be included. Indeed, the rapid recovery phase after a stroke lasts about 3 weeks and it is difficult to interpret rapid clinical changes and to attribute them to the treatment (since investigator team do not know the time of onset of the effect of mepivacaine) over this temporal period.
Mepivacaine will be administered as a single injection, subcutaneously, at a dose of 3 mL of mepivacaine hydrochloride (20 mg/mL), or 60mg. If mepivacaine is effective, research participants will experience a temporary reduction in neurological symptoms.
Time course of experiment
Verification of inclusion and exclusion criteria (1h)
Evaluation of the neurological deficit before treatment (1h)
Administration of mepivacaine 7 Evaluation of the neurological deficit after treatment, at T= 1+/- 30 minutes after administration (duration 1h)
8/ MRI n°2 (duration 30 to 45min) 1h30 after administration 9/ Evaluation of the neurological deficit after treatment, at T= 3h45+/- 45 minutes after administration (duration 1h)
Brain imaging
MRI will be performed on a SIEMENS 3 Tesla machine, without injection of contrast medium. The duration of the MRI will be approximately 45 minutes to one hour for MRI n°1 (baseline) and 30 to 45 minutes for MRI n°2 performed after the injection of mepivacaine.
MRI acquisitions will include the following sequences:
Drug treatment :
Mepivacaine will be administered:
With at disposal
Genetic samples :
The gene coding for brain-derived neurotrophic factor (BDNF) is of particular interest. BDNF is a protein that contributes to neurogenesis and neuronal differentiation, participates in the creation of new synapses and influences the survival of existing neurons. It is thus currently considered as a crucial element influencing brain plasticity . This could also be an explanatory factor in identifying responders to mepivacaine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
mepivacaine injection
Drug: Carbocaine Injectable Product
One injection per patient
improvement of clinical scores
The response is defined as an improvement 1h (+/- 30min) after injection, compared to the evaluation before mepivacaine injection, on at least one of the clinical scores specific to the symptoms: * language : decrease of at least 4 points on the ART scale (rated from 0 to 26) , or increase of 20% of the number of images correctly named on a standardized battery (DO80, rated from 0 to 80). The rate of 20% corresponds to an effect considered clinically significant, without any "clinically significant minimal change" published to date. * motor skills : increase of at least 4 points on the Fugl-Meyer scale (rated from 0 to 60) corresponding to the "clinically significant minimal change" in the re-education studies * visual field : 20% reduction of a scotoma evaluated in automated static perimetry of Humphrey by the number of deficit areas compared to the total number of areas evaluated (n=43). The rate of 20% corresponds to an effect considered clinically significant
Time frame: 1 Day
language-related symptoms
Relative change, in percentage, in the number of correctly named images on a standardized battery (DO80, rated from 0 to 80) between pre- and 1h(+/-30min) post-injection to measure language-related symptoms.
Time frame: 1 Day
ART scale
Absolute change, in number of points, on the ART scale (rated from 0 to 26) between before and 1h(+/-30min) after injection to measure language-related symptoms.
Time frame: 1 Day
spontaneous language test
Relative change, of he rate from 0 to 10 at the spontaneous language test between before and 1h(+/-30min) after injection to measure language-related symptoms.
Time frame: 1 Day
Fugl-Meyer scale
Absolute change, in number of points, on the Fugl-Meyer scale (rated from 0 to 60), between before and 1h(+/-30min) after injection to measure motor symptoms.
Time frame: 1Day
Timed up and go test
relative change, on the Timed up and go test (TUG) (rated in seconds), between before and 1h(+/-30min) after injection to measure motor symptoms.
Time frame: 1Day
10 metres walking test
Relative change, on the 10 metres walking test (rated in seconds), between before and 1h(+/-30min) after injection to measure motor symptoms.
Time frame: 1Day
Perimetry of Humphrey
Relative evolution of visual symptoms, measured in automated static perimetry of Humphrey (STAT-30, Metrovision) by the number of deficit areas compared to the total number of assessed areas (n=43), between before and 1h (+/-30min) after injection
Time frame: 1 Day
kinetic perimetry
Relative evolution of visual symptoms, measured in kinetic perimetry by the surface of isoptera III/4, between before and 1h (+/-30min) after injection.
Time frame: 1 Day
static perimetry
Evolution of visual deficit volumes, measured in static perimetry in dB.deg2, between before and 1h (+/-30min) after injection.
Time frame: 1 Day
NIHSS score changes
Change in severity of neurological sequelae measured by the relative change in the National Institutes of Health Stroke Scale (NIHSS score) between before and 1h(+/-30min) after injection.
Time frame: 1 Day
response delay
Patient Reported Response Start and End Times
Time frame: 1 Day
Started Jun 2022 (actual). Primary completion is estimated for Jun 2024, 24 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 24 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mepivacaine
Assistance Publique - Hôpitaux de Paris →